Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.54 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911969 | 0.90 | MGLL (0.57) | MGLLKCNH2MALT1PTGS2MEN1 | |
| SCHEMBL2917069 | 0.90 | MGLL (0.57) | MGLLKDM1AKCNH2MALT1PTGS2 | |
| SCHEMBL13627396 | 0.90 | MGLL (0.68) | MGLLKCNH2MALT1PTGS2MEN1 | |
| SCHEMBL2920388 | 0.89 | MALT1 (0.61) | MGLLKCNH2MALT1PTGS2MEN1 | |
| SCHEMBL13637494 | 0.89 | MGLL (0.56) | MGLLKCNH2MALT1PTGS2MEN1 | |
| SCHEMBL2911623 | 0.89 | MGLL (0.56) | MGLLKDM1AKCNH2MALT1PTGS2 | |
| SCHEMBL2917284 | 0.89 | MGLL (0.63) | MGLLKCNH2MALT1PTGS2 | |
| SCHEMBL2910679 | 0.86 | MGLL (0.53) | MGLLKDM1AKCNH2MALT1PTGS2 | |
| SCHEMBL2917646 | 0.86 | MGLL (0.58) | MGLLPTGS2 | |
| SCHEMBL5265747 | 0.85 | MGLL (0.51) | MGLLKCNH2MALT1PTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | MGLL 2165/4885KDM1A 2661/4885KCNH2 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.